Search results for "From ACP Journal Club"
Glargine and liraglutide improved glycemic outcomes at 5 y vs. glimepiride or sitagliptin, while liraglutide reduced CV events vs. glargine, glimepiride, or sitagliptin
Although microvascular complications and death were not materially different among the four treatment groups in a recent trial, the results do allow inferences about the role of sulfonylureas and dipeptidyl peptidase-4 inhibitors in practice, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2023/01/13/8.htm
13 Jan 2023
In diabetes, some statins reduce non–HDL-C better than others vs. placebo
A review reaffirmed well-known information about the potency of commonly prescribed statins and suggested that non–high-density lipoprotein cholesterol (HDL-C) may be a better measure of cardiovascular risk than low-density lipoprotein cholesterol in patients on statins, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/08/12/6.htm
12 Aug 2022
In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality
The results of the meta-analysis support recommendations to use sodium-glucose cotransporter-2 (SGLT2) inhibitors or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in diabetes patients who have or are at high risk for cardiovascular (CV) disease, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/03/11/8.htm
11 Mar 2022
KDIGO made 12 recommendations for managing diabetes with CKD
The kidney group's guideline supports metformin and sodium–glucose cotransporter-2 inhibitors as first-line therapies for patients with chronic kidney disease (CKD) based on consistent trial data showing their effectiveness, noted an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2021/03/12/6.htm
12 Mar 2021
In type 2 diabetes, the BT-001 smartphone app reduced HbA1c more than a control app at 90 d
The availability of an app that delivers cognitive behavioral therapy to patients with diabetes could have meaningful clinical effects, but it remains to be seen whether behavior changes are sustained long-term, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2023/01/13/10.htm
13 Jan 2023
In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors
A cohort study's finding of increased risk of diabetic ketoacidosis with sodium-glucose cotransporter-2 (SGLT2) inhibitors is relevant to clinical decision making, but not definitive given the limitations of observational research, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/01/08/6.htm
8 Jan 2021
Patients surviving COVID-19 had increased risk for incident diabetes vs. persons without COVID-19
Although the effect of COVID-19 on diabetes incidence is small, according to the study, the affected population could be large, given that many at-risk people have had acute COVID-19, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/08/12/7.htm
12 Aug 2022
In T2DM, weekly insulin icodec did not differ from daily glargine for reducing HbA1c or significant/severe hypoglycemia
An ACP Journal Club commentary pointed out that use of once-weekly insulin for patients with type 2 diabetes will require more cautious dose-titration algorithms and less stringent glycemic targets to avoid hypoglycemia.
https://diabetes.acponline.org/archives/2021/03/12/7.htm
12 Mar 2021
GLP-1 RA plus SGLT-2 inhibitor vs. either drug alone reduces HbA1c and SBP
The finding that combining glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors improves glycemic control and systolic blood pressure (SBP) without increasing hypoglycemia is important, but additional cost-effectiveness research on the drugs is needed, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2020/12/11/9.htm
11 Dec 2020
SGLT2 inhibitors increase risk for diabetic ketoacidosis in type 2 diabetes
Diabetic ketoacidosis (DKA) is rare with sodium-glucose co-transporter-2 (SGLT2) inhibitors but more common than with control medications, and clinicians should be vigilant in identifying euglycemic DKA in patients on these drugs, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2020/11/13/6.htm
13 Nov 2020